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Abstract
Purpose To compare mutation analysis of cytology speci-
mens and 99mTc-MIBI thyroid scintigraphy for differentiating
benign from malignant thyroid nodules in patients with a cy-
tological reading of follicular neoplasm.
Methods Patients ≥18 years of age with a solitary
hypofunctioning thyroid nodule (≥10 mm), normal thyrotro-
pin and calcitonin levels, and a cytological diagnosis of follic-
ular neoplasm were prospectively enrolled. Mutation analysis
and 99mTc-MIBI scintigraphy were performed and patients
were subsequently operated on to confirm or exclude a malig-
nant lesion. Mutations for KRAS, HRAS and NRAS and for
BRAF and translocations of PAX8/PPARγ, RET/PTC1 and
RET/PTC3 were investigated. Static thyroid scintigraphic im-
ages were acquired 10 and 60 min after intravenous injection
of 200 MBq of 99mTc-MIBI and visually assessed. Addition-
ally, the MIBI washout index was calculated using a semi-
quantitative method.
Results In our series, 26 % of nodules with a follicular pattern
on cytology were malignant with a prevalence of follicular
carcinomas. 99mTc-MIBI scintigraphy was found to be signif-
icantly more accurate (positive likelihood ratio 4.56 for visual
assessment and 12.35 for semiquantitative assessment) than
mutation analysis (positive likelihood ratio 1.74). A negative
99mTc-MIBI scan reliably excluded malignancy.
Conclusion In patients with a thyroid nodule cytologically
diagnosed as a follicular proliferation, semiquantitative anal-
ysis of 99mTc-MIBI scintigraphy should be the preferred meth-
od for differentiating benign from malignant nodules. It is
superior to molecular testing for the presence of differentiated
thyroid cancer-associated mutations in fine-needle aspiration
cytology sample material.
Keywords Thyroid . Follicular neoplasms . Fine-needle
aspiration cytology . 99mTc-MIBI .Molecular markers .
Scintigraphy .Mutation analysis
Introduction
The diagnostic approach to thyroid nodules is usually based
on clinical examination, ultrasonography (US) and scintigra-
phy in suspicious nodules followed by the well-established
complementary procedure of fine-needle aspiration cytology
(FNAC) [1]. However, the most important limitation of
FNAC is the lack of accuracy in discriminating between ma-
lignant follicular carcinoma and benign follicular adenoma
because of its inability to detect capsular invasion and vascular
infiltration of the tumour [2]. An additional limitation is the
fact that there are some patients with follicular variants of
papillary carcinoma in whom the classic diagnostic cytologi-
cal criteria of papillary carcinoma are lacking (i.e. papillary
structures) or not completely unequivocal (i.e. nuclear
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features) [3]. Furthermore, in some patients with a
microfollicular goitre with a hypercellular pattern, diagnosis
by FNAC may be a challenge [4]. As a consequence, any
nodule diagnosed as a follicular neoplasia on FNAC requires
surgical excision for definitive histopathological diagnosis [2,
4]. However, the great majority of such cases turn out to be
histologically benign. Hence, the identification of new diag-
nostic approaches to provide reliable preoperative criteria for
malignancy in patients with indeterminate FNAC is of para-
mount importance to reduce the number of unnecessary thy-
roid surgery procedures. Different additional tools have been
proposed to increase preoperative accuracy in the assessment
of nodules with a follicular pattern on FNAC including US,
core-needle biopsy and elastosonography. Unfortunately,
none of these has proved to be adequate to safely rule out
the need for diagnostic surgery in follicular neoplasms [5–7].
Thyroid scintigraphy with 123I-iodide or 99mTc-
pertechnetate is a well-established tool for ruling out malig-
nancy in hyperfunctioning (i.e. hot) nodules, while thyroid
99mTc-methoxyisobutylisonitrile (99mTc-MIBI) scanning has
been proposed for differentiating benign from malignant
hypofunctioning (i.e. cold) thyroid nodules [1]. 99mTc-MIBI
uptake within the nodule reflects the abundance of actively
functioning mitochondria in the nodule and therefore its oxi-
dative burden. In turn, increased uptake and late retention of
the tracer within the nodule indicate a high probability of a
malignant thyroid nodule [1, 8]. Accordingly, many studies
and a recent meta-analysis have demonstrated that a 99mTc-
MIBI scan is a sensitive diagnostic tool for predicting or ex-
cluding malignancy of hypofunctioning thyroid nodules, thus
leading to a lower rate of unnecessary thyroidectomies [9–16].
More recently attempts to refine the cytological diagnosis
of follicular neoplasms have also involved the molecular test-
ing of thyroid FNAC samples. Two main types of molecular
test are currently available: mutation analysis panels and
Afirma® gene expression classifier (GEC). Themutation anal-
ysis panels determine the presence of single gene point muta-
tions (i.e. BRAF, RAS) or gene translocations (i.e. RET/PTC,
PAX8/PPARγ). It has been estimated that one of these muta-
tions is present in approximately 70 % of differentiated thy-
roid cancers (DTC); consequently nodules harbouring these
mutations or translocations have a high likelihood of cancer,
giving this test a high positive predictive value (PPV) [17].
However, a significant number (6 – 28 %) of malignant nod-
ules do not harbour one of these genetic markers and, addi-
tionally, RAS mutations can be commonly found in benign
adenomas [18]. The Afirma test employs a proprietary GEC.
After RNA extraction and nucleic acid amplification, proc-
essed GEC samples are hybridized to a customAfirma thyroid
microarray and analysed with a classification algorithm using
linear support vector machine logic to produce either a
Bbenign^ or Bsuspicious^ test result. Validation studies have
demonstrated a high negative predictive value (NPV) among
nodules with indeterminate cytology [19] and the Afirma
GEC has been reported to obviate the need for surgical exci-
sion in about 50 % of cases [20]. However, a substantial num-
ber of benign nodules do not have a gene expression profile
classified as benign and the categorization of a nodule as
Bsuspicious^ carries a cancer risk of only 38 % [18].
It is unclear whether molecular imaging or molecular test-
ing is better for the identification of malignant follicular lesions.
The aim of the present study was to prospectively investigate
and compare the clinical performance of the mutation analysis
panel and 99mTc-MIBI thyroid scintigraphy in differentiating
benign from malignant thyroid nodules in patients with a cyto-
logical reading of (suspicious for) follicular neoplasm.
Materials and methods
Patients
All patients were diagnosed and treated at the Division of Nu-
clear Medicine and Thyroid Centre, Oncology Institute of
Southern Switzerland, Bellinzona (Switzerland) between 1 Jan-
uary 2010 and 31 December 2014. Enrolled were adult patients
(i.e. age ≥18 years) with: (1) normal thyrotropin (TSH) and
calcitonin levels; (2) a solitary hypofunctioning, thyroid nodule
≥10 mm in maximum diameter, with a suspicious US pattern;
and (3) a cytological diagnosis of (suspicious for) Bfollicular
neoplasm^. Mutation analysis on FNAC specimens and 99mTc-
MIBI scintigraphy were performed, and patients were subse-
quently operated on to confirm or exclude a malignant lesion.
The study was approved by the Oncology Institute of Southern
Switzerland Scientific Advisory Board and by the Ethics Com-
mittee of Canton Ticino (Bellinzona, Switzerland), and written
informed consent was obtained from each patient.
TSH and calcitonin measurement
TSH and calcitonin were measured using an IMMULITE®
2000XPi platform (Siemens Healthcare Diagnostics, Erlangen,
Germany). The normal limits were 0.40 – 4.00mUI/L for TSH,
and <8.4 ng/L (in men) and <5 ng/L (in women) for calcitonin.
Thyroid ultrasonography
All US examinations were performed by the same physician
(L.G.) with more than 20 years experience in thyroid US. An
Acuson® S3000 sonograph equipped with a small-parts mul-
tifrequency (5 – 13 MHz) probe (Siemens, Erlangen, Germa-
ny) was used. Thyroid nodules were assessed according to the
thyroid imaging reporting and data system (TI-RADS) classi-
fication [21] (i.e. 1 normal, 2 benign, 3 probably benign, 4A
undetermined pattern, 4B suspicious pattern, 5 consistent with
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malignancy), and nodules with a score of 4B or 5 were re-
ferred for US-guided fine-needle aspiration.
99mTc-Pertechnetate thyroid scintigraphy
99mTc-Pertechnetate scintigraphy was performed using a large
field-of-view γ-camera (Symbia-T2; Siemens, Erlangen,
Germany) equipped with an ultrahigh-resolution parallel-hole
low-energy collimator. Freshly eluted 99mTc pertechnetate
(74 MBq; Mallinkrodt, Petten, The Netherlands) was injected
intravenously, and after 15 min a static image of the neck was
acquired in the anterior view with a 128×128 matrix, using a
digital zoom of 2 (pixel dimension 2.4 mm). The acquisition
time was set to 300 s with a 20 % window centred at 140 keV
in all cases. Thyroid scans were evaluated by an experienced
nuclear medicine physician with more than 20 years experi-
ence in the field (L.G.) and nodules were assessed as hyper-
functioning (uptake in the nodule > uptake in normal thyroid
tissue), functionally normal (uptake in the nodule = uptake of
normal thyroid tissue) or hypofunctioning (uptake in the nod-
ule < uptake in normal thyroid tissue.
99mTc-MIBI thyroid scintigraphy
The tracer 99mTc-MIBI was prepared using a commercially
available kit (STAMICIS®; IBA, Gif-sur-Yvette, France)
using freshly eluted99mTc pertechnetate (see above). Labelling
efficiency was assessed by thin-layer chromatography and
was found to always exceed 95 %. 99mTc-MIBI (200 MBq)
was injected intravenously, and after 10 and 60 min static
images of the neck were acquired in the anterior view with a
128×128 matrix, using a digital zoom of 2 (pixel dimension
2.4 mm). The acquisition time was set to 600 s with a 20 %
window centred at 140 keV in all cases.
99mTc-MIBI scan assessment
Before surgery images were independently assessed by two
nuclear medicine physicians with more than 20 years experi-
ence in the field (L.C., A.C.). They used both a visual scoring
method and a semiquantitative technique, and were not aware
of the clinical data or the results of cytological and molecular
analysis. If they disagreed, they discussed the case and
reached a consensus in all cases.
Visual analysis
The 99mTc-pertechnetate and 99mTc-MIBI (early and delayed)
thyroid images of a given patient were placed side by side for
comparison. The visual assessment used the following scoring
system: pattern 1 no increased uptake of 99mTc-MIBI within
the nodule in comparison to the 99mTc-pertechnetate scan on
either the early or delayed image, pattern 2 increased uptake
on the early image that had decreased on the delayed image,
and pattern 3 increased uptake on the early image that
remained unchanged or had further increased on the delayed
image. Pattern 3 was considered suspicious for malignancy
and patterns 1 and 2 were both considered negative for malig-
nancy of the thyroid nodule concerned. The different scinti-
graphic patterns are illustrated in Fig. 1.
Semiquantitative analysis
On each early image, a region of interest (ROI) was drawn
over the perimeter of the thyroid nodule and thenmoved to the
opposite normal lobe; additionally, background ROIs were
drawn above the inferior pole of thyroid lobe. These ROIs
were then copied from the early to the delayed images. The
mean count in each ROI was determined, and the early and
delayed uptake results (EUR and DUR) were calculated by
subtracting the count in normal tissue (after correction for
background activity) from the nodule count. The washout in-
dex (WOInd) was then calculated using the formula
WOInd= [(DUR/EUR×100) − 100].
Fine-needle aspiration cytology
Preoperative FNAC was performed under ultrasound guid-
ance with a 22-gauge needle attached to a 10-mL plastic sy-
ringe by a nuclear medicine physician (L.G.) and a cytopa-
thologist (M.B.) both with more than 20 years experience in
fine-needle aspiration procedures. Some of the aspirated fluid
was expelled and smeared onto charged slides, alcohol-fixed
and processed for Papanicolaou staining, or air-dried and
processed for Giemsa staining. The remaining material was
fixed in PreservCyt solution and used to prepare liquid-based
cytological slides and in some cases to prepare an additional
Cytoblock cell block. Oncocytic follicular neoplasms were
considered to be present if at least 50 % of the total follicular
cells were large cells with abundant deeply eosinophilic and
granular cytoplasm and hyperchromatic nuclei with promi-
nent nucleoli. The same cytopathologist (M.B.) evaluated all
cytological samples and the results were scored according to
the Bethesda system [22]: class I nondiagnostic, class II be-
nign, class III indeterminate/atypical, class IV (suspicious for)
follicular neoplasm, class V suspicious for malignancy, and
class VImalignant. Patients with a cytological reading of (sus-




Molecular tests were performed using laser capture microdis-
section (LCM) as previously described [23]. Briefly, one
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representative slide for each FNAC sample was incubated in
xylene for 1 – 5 days to remove the cover slips and then
processed for LCM using a laser microdissection system
(PALM MicroBeam; Carl Zeiss Microscopy GmbH, Germa-
ny). For DNA analysis at least six microfollicular structures
were dissected and catapulted in a tube cup containing 15 μl
of ATL tissue lysis buffer (QIAamp mini kit; Qiagen,
Chatsworth, CA). For RNA analysis, six additional
microfollicular structures from the same slide were dissected
and catapulted in a second tube cap containing 15 μl of RLT
buffer (RNeasy micro kit; Qiagen). Genomic DNA was then
extracted using the QIAamp mini kit according to the manu-
facturer’s instructions. RNAwas extracted using the RNeasy
micro kit. cDNAwas prepared starting from 7.5 μL of RNA
with SuperScript II reverse transcriptase (Invitrogen, Carls-
bad, CA) according to the manufacturer’s instructions.
Genetic analyses
Mutations for KRAS, HRAS and NRAS (exons 2 and 3, con-
taining hotspot codons 12, 13 and 61) and for BRAF (exon 15,
containing the region surrounding the hotspot codon 600)
were investigated by direct sequencing of genomic DNA
and analysed with Sequence Navigator software (Thermo
Fisher Applied Biosystems, Foster City, CA) as previously
described [24, 25]. The PAX8/PPARγ fusion transcripts, the
two main forms of RET/PTC translocations (RET/PTC1 and
RET/PTC3), and the two internal control genes (PAX8 and
PGK1) were analysed by reverse transcription polymerase
chain reaction (RT-PCR) and the fragments were subsequently
analysed using an ABI PRISM 3130 genetic analyser (Ther-
mo Fisher) according to previously published protocols [26,
27], and then analysed with GeneMapper® software 5 (Ther-
mo Fisher). All mutations or gene translocations were con-
firmed at least twice starting from independent PCR reactions.
Synthetic DNA containing genomic regions involved in
PAX8/PPARγ translocations as well as plasmids containing
RET/PTC1 and RET/PTC3 fusion genes were used as positive
controls.
Statistical analysis
Histological diagnosis on the surgical specimens was regarded
as the reference standard. The Mann-WhitneyU test was used
to evaluate the differences in EUR, DUR and WOInd between
benign and malignant lesions. Receiver operating characteris-
tic analysis was performed to determine the WOInd threshold
above which malignant thyroid nodules could be detected.
The results were considered significant when the p value
was less than 0.05. Sensitivity, specificity, PPV, NPV, likeli-
hood ratio, and diagnostic accuracy of mutational analysis and













Fig. 1 Visual assessment of
99mTc-MIBI scintigraphy. a
99mTc-pertechnetate; b 99mTc-
MIBI (early image); c 99mTc-
MIBI (delayed image) Pattern 1
no early/delayed uptake within
the nodule, pattern 2 early uptake
with late decrease pattern 3 early
uptake stable or increasing on de-
layed images
Eur J Nucl Med Mol Imaging (2016) 43:1018–1026 1021
computed for benign versus malignant lesions. Statistical
analyses were performed using Stats Direct version 2.8
(StatsDirect Ltd, Altrincham, UK)
Results
Among 1,478 patients referred to our centre for thyroid nodule
evaluation between 1 January 2010 and 31 December 2014
included were 61 consecutive patients (17 men and 44 wom-
en; age range 24 – 81 years, median 55 years) with a solitary
thyroid nodule of at least 10 mm in diameter (median 22 mm,
range 10 – 42 mm), hypofunctioning on 99mTc-pertechnetate
scan, suspicious on US examination. and cytologically classi-
fied as B(suspicious for) follicular neoplasm^ (i.e. Bethesda
class IV). Demographic and clinical data, cytopathology find-
ings and the results of mutation analysis and 99mTc-MIBI
scintigraphy are summarized in Table 1. Overall, 16 (26 %)
of the 61 nodules were malignant (5 follicular carcinomas; 5
follicular carcinomas, Hürthle cell variant; 3 papillary carci-
nomas; 2 papillary carcinomas, follicular variant; 1 poorly
differentiated thyroid carcinoma) and 45 (74 %) were benign
(37 follicular adenomas; 3 follicular adenomas, Hürthle cell
variant; 5 hyperplastic nodules).
Mutation analysis
Neither BRAF mutations nor RET/PTC translocations were
found in our series. PAX8/PPARγ mutations were found in
one follicular carcinoma and two follicular adenomas, respec-
tively. RAS mutations were found in three malignant nodules
(one follicular, one papillary and one poorly differentiated
carcinoma) and one follicular adenoma. Overall, mutational
analysis was positive in four malignant and three benign fol-
licular proliferations (sensitivity 25 %, specificity 94 %, accu-
racy 80 %, PPV 57 %, NPV 77 %). The positive likelihood
ratio was 1.74 (95 % CI 0.94 – 4.78).
99mTc-MIBI scintigraphy
Visual analysis
Among 16 malignant nodules, 10 (62 %) showed scintigraph-
ic pattern 3, and 6 (38 %) pattern 2. Among 45 benign nod-
ules, 2 (4 %) showed pattern 3, 31 (69 %) pattern 2, and 12
(27 %) pattern 1. Considering patterns 1 and 2 as negative for
malignancy, the sensitivity, specificity and accuracy of 99mTc-
MIBI visual analysis in differentiating benign from malignant
nodules were 62 %, 95 % and 87 %, respectively. PPV and
NPV were 83 % and 88 %, respectively. The positive likeli-
hood ratio was 4.56 (95 % CI 1.94 – 9.54).
Semiquantitative analysis
The WOInd cut-off corresponding to the highest accuracy for
discriminating between benign and malignant follicular pro-
liferations was settled at −9. Among 18 nodules with a WOInd
between 0 and −9, 16 had a histological result consistent with
malignancy (i.e. true-positive) whereas 2 were histologically
benign (i.e. true-negative). The remaining 43 lesions with a
WOInd equal to or below this cut-off were histologically be-
nign. For this threshold, the sensitivity, specificity and accu-
racy were 100 %, 96 % and 98 %, respectively. The PPVand
NPV were 88 % and 100 %, respectively. The positive likeli-
hood ratio was 12.35 (95 % CI 8.76 – 21.45). The area under
the receiver operating characteristic curve was 0.980.
Discussion
In our series, 26 % of nodules with a follicular pattern on
cytology were malignant with a prevalence of follicular carci-
nomas. These results probably reflect an accurate cytological
classification that avoided both the upstaging of atypical fea-
tures (class III) and the downstaging of suspicious papillary
cancers (class V) to class IV. In turn, most Bfollicular
neoplasms^were confirmed to be follicular cancer or follicular
adenomas. In this setting, the present study showed that mo-
lecular analysis for the presence of DTC-associated genetic
mutations is poorly sensitive (i.e. only one in four malignant
nodules showed almost one mutation/translocation) and not
accurate enough to obviate the need for surgery in patients with
negative results (i.e. NPV 77 %). Neither BRAFmutations nor
RET/PTC translocationswere found in our patients. This result
may be partially explained by the low number of papillary
carcinomas in our series. However, a recent meta-analysis of
the literature [28] has confirmed the very limited role of BRAF
mutation analysis in nodules with a follicular pattern on cytol-
ogy. In addition, among seven nodules with PAX8/PPARγ
mutations and/or RAS translocations, four were malignant
and three benign, leading to a very poor sensitivity and NPV.
Interestingly, visual pattern 1 on 99mTc-MIBI scintigraphy
(i.e. MIBI uptake lower than or equal to Tc uptake within the
nodule) had a very high NPV, correctly excluding malignancy
in 100 % of patients. However, this pattern is not frequent in
benign follicular proliferations (12 of 45 patients in our se-
ries). Furthermore, an overlap between carcinomas and benign
lesion was observed in nodules with scintigraphic pattern 2 or
3, resulting in a suboptimal sensitivity and PPV for visual
analysis as a whole. In contrast, the semiquantitative analysis
of 99mTc-MIBI scintigraphy showed a better diagnostic per-
formance than visual analysis in correctly identifying thyroid
nodules cytologically classified as Bfollicular neoplasm^ as
benign or malignant, respectively. Using this semiquantitative
method with the thresholds described here, very high levels of
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sensitivity, specificity, PPV, NPV and accuracy can be
achieved. Certainly the present results show that in patients
with equivocal 99mTc-MIBI scintigraphy (i.e. pattern 2 or 3), a
semiquantitative analysis should be performed to achieve a
diagnostically useful result. Our results are largely in line with
those previously obtained by Saggiorato et al. [12] in a series
of 51 patients with follicular proliferation.
The sensitivity, specificity, accuracy, PPV and NPV of
99mTc-MIBI in differentiating benign from malignant non-
oncocytic tumours were 73 %, 81 %, 78 %, 73 % and 81 %
for visual analysis and 100%, 90%, 95%, 88% and 100% for
semiquantitative analysis. In contrast, the diagnostic perfor-
mance of both visual and semiquantitative analysis dramatically
worsened in oncocytic lesions. Indeed, the diagnostic accuracy
of 99mTc-MIBI visual analysis was only 33 %, and no signifi-
cant differences in the semiquantitative indices were observed
between malignant and benign oncocytic thyroid nodules.
As oncocytic cells (both benign and malignant) are rich in
mitochondria, it can be expected that most benign oncocytic
lesions will also be positive. In our series eight patients with
oncocytic follicular proliferations (five malignant and three be-
nign) were included; in contrast to the study by Saggiorato et al.
[12], we were able to accurately discriminate benign from ma-
lignant lesions using semiquantitative analysis. It can therefore be
surmised that either mitochondrial density or blood flow is great-
er in malignant that in benign oncocytic proliferations, or both.
This better performance in our study may be due to the compar-
atively high proportion of patients withmalignant oncocytic nod-
ules in our series which may have positively affected specificity
and PPV. The high incidence of malignant oncocytic nodules
among the patients in our series (60%) compared to the literature
(30%) is well explained by the size of these lesions. Three of five
malignant oncocytic nodules were larger than 40 mm, which in
itself would be associated with a risk of malignancy of about
80%. However, considering the still low number of patients with
oncocytic lesions, no definitive specific conclusions can be
drawn from the present study. Therefore, based on the present
and previous data , we advise caution in employing 99mTc-MIBI
scanning in lesions cytologically diagnosed as oncocytic follicu-
lar proliferations. Nevertheless, as reported by Boi et al. [29], a
visually negative scan strongly supports the absence ofmalignant
oncocytic proliferation. Finally, molecular testing of FNAC ma-
terial for the presence of DTC-associated mutations/
translocations was clearly inferior to 99mTc-MIBI scanning in
our series, and should therefore not be considered for clinical
routine for identifying follicular neoplasms.
Some limitations of the present study should also be
discussed. First, the semiquantitative analysis is at least par-
tially an operator-dependent technique, especially with re-
gard to the definition of the ROIs. Furthermore, this tech-
nique is partially dependent on the instruments used and the
peculiarities of the local patient population. Therefore, each
laboratory needs to optimize the protocol and to define its
own WOInd cut-off. Second, these results were obtained in
patients prospectively evaluated in a single referral centre
and need to be confirmed on a larger, multicentre population
before universal adoption of this technique can be consid-
ered. Third, no data are available in the literature on direct
prospective comparisons between 99mTc-MIBI scan and
Afirma GEC. Heinzel et al. [30] recently compared the pub-
lished results of Afirma and molecular imaging with 99mTc-
MIBI and found that the latter is superior both in terms of
life-years gained and cost/effectiveness. However, head-to-
head comparisons in the same patient population are needed
to clarify this issue. Notwithstanding these limitations, our
results suggest that semiquantitative 99mTc-MIBI could be a
highly accurate presurgical method for investigating follic-
ular lesions, predicting the malignant behaviour of thyroid
nodules that are indeterminately diagnosed as follicular pro-
liferations on FNAC. The use of this technique has great
potential to reduce the number of diagnostic thyroid surgi-
cal procedures performed in patients with follicular prolif-
erations without a great risk of missing DTC. However,
based on the present results semiquantitative analysis may
be unnecessary if 99mTc-MIBI scintigraphy is unequivocal-
ly negative, i.e. no mismatch compared to 99mTc-
pertechnetate scintigraphy.
Conclusion
In patients with a thyroid nodule cytologically diagnosed as
follicular proliferation, semiquantitative analysis of 99mTc-
MIBI scintigraphy should be the preferred method for differ-
entiating benign frommalignant nodules. It is superior to both
purely visual interpretation of 99mTc-MIBI scintigraphy and to
molecular testing for the presence of DTC-associated muta-
tions in FNAC sample material.
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